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Focal and diﬀerential therapy represent an approach to improve the therapeutic ratio of prostate cancer treatments. This concept
is a shift from treating the whole gland to intensely treating the portion of the gland that contains signiﬁcant tumor. However,
there are many challenges in the move towards focal approaches. Deﬁning which patients are suitable candidates for focal therapy
approaches is an area of signiﬁcant controversy, and it is likely that additional data from imaging or detailed biopsy methods is
needed in addition to traditional risk factors. A number of methods have been suggested, and imaging with multiparametric MRI
and transperineal template mapping biopsy have shown promise. The approach of diﬀerential therapy where the entire prostate
is treated to a lower intensity and the tumor areas to high intensity is also discussed in detail. Radiation therapy is a well suited
modality for the delivery of diﬀerential therapy. Data in the literature using external beam radiation, high dose rate brachytherapy,
and low-dose rate brachytherapy for diﬀerential therapy are reviewed. Preliminary results are encouraging, and larger studies and
randomized controlled trials are needed to validate this approach.
1.Introduction
Prostate cancer is the most common malignancy in men in
the US, with an estimated 241,740 cases to be diagnosed
in the US in 2012 [1]. The widespread acceptance and
implementation of PSA screening beginning in the early
1990s have also led to a shift to a greater number of cases
diagnosed with earlier stage disease. From 1989 to 1992
the percentage of cases diagnosed with low-risk disease
in the US was 29.8%, and this increased to 45.3% from
1999 to 2001 [2]. While many men with low-risk disease
are well managed by surveillance [3], a large number of
patients need or choose treatment. Deﬁnitive treatments
such as brachytherapy, external beam radiation therapy, or
radical prostatectomy generally provide high success rates
with biochemical control and disease speciﬁc survival of 80–
90% or higher for low-risk disease [4–6]. However, these
proceduresareassociatedwithsexual,urinary,andrectalside
eﬀects that may impact patient quality of life and overall
satisfaction of treatment outcome [7].
Focal therapy represents an approach to improve the
therapeutic ratio by maximizing tumor control while min-
imizing side eﬀects. Whereas traditional therapies typically
treat the entire prostate gland, this concept is a shift
towards intensely treating the portion of the gland that
contains signiﬁcant tumor. This targeted treatment strategy
has the potential to reduce the chance of injury to adjacent
organs and resultant side eﬀects while maintaining excellent
oncologic outcomes. However, there are many challenges in
the move towards focal therapy including identifying appro-
priate candidates, methodology of identifying intraprostatic
tumor, and whether the remaining prostate gland should
receive some form of treatment.
2. Candidatesfor Focal Approaches
Deﬁning which patients are suitable candidates for focal
therapy approaches is an area of signiﬁcant controversy.
Patients in the low-risk group, with the excellent outcomes2 Advances in Urology
described above, would appear to be the most logical choice
for deintensiﬁcation of treatment. Strict low-risk criteria
were used by Katz et al. (Gleason < 7, PSA < 10, <T2b,
only 1 biopsy core positive, no larger than 80% of a single
core, no perineural invasion noted) to attempt to identify
patients who could adequately be treated by focal therapy
[8]. However, when 56 patients with these characteristics
underwent radical prostatectomy, 12 (21%) were found to
have signiﬁcant bilateral secondary tumor, and thus the
authors concluded that these criteria alone could not be used
to select for focal therapy candidates. A consensus panel of
international experts at the 2nd International Workshop on
Focal Therapy and Imaging in Prostate and Kidney Cancer
has issued recommendations on candidate selection for focal
therapy [9]. They recommended that candidates for focal
therapy should be limited to patients of low or moderate
risk, and any patients with dominant Gleason 4 or clinical
stage T2b or greater should be excluded. In addition, to
these traditional risk factors, they also recommended that
patients should undergo transperineal template mapping
biopsies or multiparametric MRI with TURS biopsy. These
recommendations underscore the fact that the clinician
who is considering focal therapy must be able to deﬁne
the anatomic location and extent of disease. As newer
methodsofidentifyingintraprostatictumorevolve,thesewill
be incorporated into both patient selection and treatment
planning for focal therapy.
3.IdentifyingIntraprostaticTumor
The current standard of care for prostate biopsy is to
use transrectal ultrasound (TRUS) guidance to take 6–12
transrectal needle biopsies throughout the prostate in a
systematic fashion. Although a reasonable approach when
whole gland treatment is being considered, a comparison
with prostatectomy specimens has shown that this method
missesanumberofclinicallysigniﬁcantcancersandisinade-
quatetoidentify candidates forfocaltherapy[10].Increasing
the number of cores as in the saturation biopsy method still
misses clinically signiﬁcant cancer in 31% of patients [11].
Three-dimensional transperineal prostate mapping biopsy
usingatemplategridisonewayofprovidingamoreaccurate
mapping of the prostate using biopsy. Preliminary studies
using this method have shown good results [12], although
detailed studies comparing it to radical prostatectomy are
still lacking. A major drawback of this method is that it is an
invasive procedure with associated complications including
ecchymoses, temporary erectile dysfunction, as well as acute
urinary retention [13].
Newer imaging modalities oﬀer a noninvasive method
of identifying tumor foci. Ultrasonic tissue type imaging
based on spectrum analysis of radiofrequency signals has
been developed by Feleppa et al., to help identify prostate
cancer. When compared to biopsy data, this method has
shown a receiver-operator characteristic curve (ROC) of
0.87 [14, 15]. This ultrasound imaging carries the advantage
of being easily incorporated into prostate biopsies and in
situ cancer treatments like brachytherapy, high-intensity
ultrasound (HIFU), and cryotherapy, which are ultrasound
based.
Magnetic resonance imaging (MRI), with the inclu-
sion of diﬀusion and dynamic contrast, has shown even
more promise in identifying intraprostatic tumors. Mul-
tiple studies have shown signiﬁcant correlation between
MRI abnormalities and radical prostatectomy specimens for
determining size and location of cancer foci [16–19]. Cancer
location and contour have been shown to have signiﬁcant
agreement with MRI [16, 17]. For example, in one study,
MRI has been shown to have sensitivity of 86%, speciﬁcity
of 94%, and receiver-operating characteristic curve of 0.874
for identifying cancer foci >0.5mL on radical prostatectomy
[18] and has in fact been shown to be accurate in detecting
cancer foci as small as 0.2cc [19]. The addition of MR
spectroscopy (MRS) may improve accuracy even further, as
Yamamura et al. found a sensitivity of 91.9% and speciﬁcity
of 98.3% for detecting prostate cancer when using the
combination of MRS and diﬀusion weighted imaging and
comparingresultstobiopsy data[20].MRSmayalsoprovide
information on cancer aggressiveness, as combinations of
metabolite ratios have been shown to correlate with Gleason
score [21].
4.Limitationsof PureFocal Treatment and
Rationale for Differential Therapy
A major dilemma in the implementation of focal therapy is
whether the shift from treating the entire gland uniformly
to purely treating the tumor only (pure focal therapy) is
too drastic and risks missing biologically signiﬁcant tumor.
Prostate cancer can be multifocal in up to 87% of patients,
and the prostate often contains three or more foci of cancer,
and sometimes as many as twelve, on radical prostatectomy
specimens [22–24]. Pretreatment risk factors have not been
reliablyabletopredictmultifocality[23],soadvancedbiopsy
or imaging methods, as described above, are needed to
deﬁne anatomic distribution of tumor. Bilaterality is also
common and was seen in 80% of radical prostatectomy
specimens in a series from the Duke Prostate Center,
although pretreatment Gleason score and percentage of
tumor involvement were found to be predictive [25]. With
bilateral disease, it is doubtful that any signiﬁcant gland
sparingcouldbeachievedifalltumorsareadequatelytreated.
In addition, the question of what constitutes a clinically
signiﬁcant tumor is a matter of controversy. Due to the
long doubling time of prostate cancer, tumor size is likely
to play a role in this determination. Analysis of prostate
cancers, found incidentally at cystoprostatectomy by Stamey
et al. suggests that cancers less than 0.5cc are not clinically
signiﬁcant [26]. However Cheng et al., found 16% of cancers
less than 0.5cc found on radical prostatectomy contained
Gleason pattern 4 and might, therefore, ultimately have
become clinically signiﬁcant [27].
Anotherdrawbackoffocaltherapyisthatthereisalackof
data on an accurate way to follow these patients. With a large
portion of the gland left untreated, traditional deﬁnitions
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consensus panel suggested that oncologic eﬃcacy would
be best achieved by interval posttreatment biopsy [9].
Multiparametric MRI may also be helpful in this situation,
for diagnosis or to target biopsies [28, 29]. The management
of local recurrence after focal therapy also presents a
challenging clinical problem—the eﬀect of focal therapy on
subsequent focal or whole gland treatments remains largely
unknown.
To address the concerns of multifocality and minimize
the chances of local recurrence, an alternative approach is
desirable. One such approach is to decrease the intensity
of the treatment to the whole prostate gland to eradicate
any small foci missed by the imaging or biopsies, while
simultaneously increasing the intensity to the identiﬁed
tumor; an approach we term diﬀerential therapy. This
approach, theoretically, will still improve the therapeutic
ratio compared to standard whole gland treatment by
decreasing the exposure of the surrounding normal tissues
to the treatment.
5. Pure Focal Therapy
The limited data that has been published thus far using
focal therapy for prostate cancer has primarily been using
HIFU, cryotherapy, and laser ablation [30–32]. Results in
highly selected patients have shown excellent control rates
and low toxicity, but followup has been short. All of these
methodsarepurefocaltherapieswithnotreatmentdelivered
to the remainder of the prostate gland. This is an inherent
limitation of these techniques, since treatment intensity is
“all or nothing.” Therefore, by themselves, these treatments
are not well suited for diﬀerential therapy. Instead, these
therapies need to be combined with another therapy to
achieve the diﬀerential therapy goal. Possible additions to
these purely focal therapies include low-dose external beam
radiotherapy or an oral 5-alpha reductase inhibitor.
6. Radiation and Differential Therapy
Radiation therapy is especially well suited to diﬀerential
therapy because the treatment intensity can be varied. With
modern technology and treatment planning techniques, the
capability exists to deliver a high dose to the tumor region
while simultaneously giving a lower dose to the remainder
of the prostate gland and adjacent organs. A dose response
relationship for prostate cancer has been well established
for both external beam radiation therapy and brachytherapy,
withhigherradiationdosestotheprostateresultinginhigher
r a t e so ft u m o rc o n t r o l[ 33–36] .L i k e w i s e ,ad o s er e s p o n s e
relationship exists for adjacent normal tissues such as
bladder,rectum,andurethrawithlowerdosestotheseorgans
correlating to a decreased incidence of side eﬀects after
radiation treatment with either external beam radiotherapy
or brachytherapy [37–40]. These dose relationships support
the hypothesis that diﬀerential therapy using radiation
therapy may improve outcomes while decreasing toxicity. In
addition, radiation treatment planning is image based, and
the information from MRI and ultrasound for intraprostatic
tumor identiﬁcation can easily be incorporated to develop a
treatment plan to achieve the diﬀerential therapy goals.
With the use of custom immobilization and image-
guided or stereotactic methods for external beam radio-
therapy, the accuracy of treatment delivery is within a few
millimeters. The combination of these techniques is an
exciting platform for the delivery of diﬀerential therapy
with external beam radiation. This approach has thus far
been explored in two ways: Miralbell et al. delivered 64Gy
external beam radiation to the entire prostate, followed by
an external beam stereotactic boost of two fractions of 5–
8Gy each to the dominant tumor region of the prostate in
50 patients [41]. The tumor region was identiﬁed based on
rectal examination, biopsy ﬁndings, and T2 MRI images.
Treatment was delivered with a customized body cast and
external markers for stereotactic guidance. They found that
the technique was feasible with a 5yr biochemical control
of 98%, and 5yr Grade 2 or greater urinary toxicity of
17.8% and rectal toxicity of 27.8%. The FLAME randomized
controlled multicenter phase III trial which is ongoing
in Europe is also using external beam radiotherapy for
diﬀerential therapy [42]. Intermediate or high-risk patients
receive 77Gy to the entire prostate, and the experimental
arm receives a simultaneous boost of 95Gy to the area of
macroscopic tumor. Multiparametric MRI is used to delin-
eate intraprostatic tumor, and implanted ﬁducial markers
are used for treatment set-up. The primary endpoint is to
evaluate whether the addition of an “ablative microboost” to
themacroscopictumorwithintheprostateincreasestheﬁve-
year freedom from biochemical failure rate compared to the
currentstandardofcare.Secondaryendpointsaretreatment-
related toxicity, quality of life, and disease-speciﬁc survival.
50 patients were registered as of October 2010, and accrual is
ongoing.
Brachytherapy is also very well suited for diﬀerential
therapy. The manual implantation of radiation sources in
combination with the rapid falloﬀ in dose as the distance
from the seeds gives the physician great ﬂexibility to vary
the treatment dose to diﬀerent parts of the prostate gland. In
addition, there are intrinsically very high doses of radiation
within a few millimeters of each source. These areas,
termed “hotspots,” contain radiation doses 2-3 times the
prescription dose, which allows for a creation of a higher
dose gradient with brachytherapy than with external beam
radiotherapy. Therefore, increasing the dose directed to the
tumor while decreasing dose to the remainder of the gland
with brachytherapy oﬀers a promising method of optimizing
outcomes while limiting side eﬀects and has been used in a
few preliminary studies in the literature.
High-dose-rate (HDR) brachytherapy has been used as
part of a diﬀerential therapy approach, by Schick et al.,
to boost the dominant intraprostatic tumor in 77 patients
[43]. The patients received 64Gy external beam radiation
therapy and then HDR brachytherapy to the tumor-bearing
regions. Tumor was identiﬁed using information from MRI,
rectal examination, and biopsy, and HDR brachytherapy
was delivered with Iridium-192 source and MRI guidance.
In this series, there was a subset of twenty patients who
received only a boost to one side of the gland only due to4 Advances in Urology
presence of unilateral tumor. The ﬁve-year biochemical
relapse free survival was 79.7% versus 70.5% (P = 0.99),
for unilaterally boosted versus bilaterally boosted patients;
however grade 4 toxicity was seen only in patients who
had bilateral brachytherapy boost (5/57, 8.8%). The authors
concluded that hemi-irradiation of the prostate with HDR
brachytherapy could be considered when patients have
rectal examination, MRI, and biopsy ﬁndings that suggest
unilateralinvolvementonly.Diﬀerentialtherapyusingpurely
HDR brachytherapy has been investigated by Pouliot et al.
at UCSF in a treatment planning study with 10 patients
[44]. MRI and magnetic resonance spectroscopy (MRS) data
was used to identify dominant intraprostatic lesions. HDR
brachytherapy treatment plans were devised to escalate the
dose to the dominant lesions while maintaining the prostate
at prescription dose and minimizing doses to adjacent
normal organs. They found that they could escalate the dose
to the dominant intraprostatic lesion to a minimum of 120%
of the prescription dose without increasing dose to adjacent
organs. Further dose escalation was feasible but resulted in
slightly higher doses delivered to the rectum and urethra.
Low-dose-rate (LDR) brachytherapy is also an eﬀective
method for diﬀerential radiation therapy. Todor et al.
suggested dual-isotope seed implants as a technique to
vary the dose throughout the prostate gland [45]. They
used MRI/MRS datasets to identify disease foci within the
prostate and generated nine LDR brachytherapy plans using
Iodine-125, Palladium-102, and Cesium-131 alone and in
combination.Theyfoundthatwiththecombinationimplant
plans, they were able to increase the biological eﬀective
dose to the tumor regions while achieving a reduction
in dose to the urethra. Gaudet et al. performed LDR
brachytherapydoseescalationtothedominantintraprostatic
lesion and reported clinical results in 120 patients [46]. The
location of the lesion was determined by sextant biopsy
information, and the involved sextant was boosted to 150%
of the prescription dose. They compared the results with
70 patients who received LDR brachytherapy with standard
treatment plans. There were no diﬀerences in acute and
late toxicities between the two groups. When comparing
the dose escalation plans to the standard plans, they found
that urethral and rectal dose parameters were lower in the
group that received higher dose to the tumors. The study
demonstrated the feasibility of diﬀerential therapy with LDR
brachytherapy without any increase in urinary, rectal, or
sexual side eﬀects. However, the use of sextant biopsy to
determine the location is limited compared to either more
extensive biopsies, or imaging methods such as ultrasound
spectrum analysis or MRI.
Ultrasound spectrum analysis as a method for iden-
tifying intraprostatic lesions is particularly attractive for
brachytherapy. Most brachytherapy is ultrasound based, and
images can be acquired at the time of the procedure and
readily incorporated into the treatment plan [47]. At our
institution, we are completing a phase I prospective trial to
evaluate the safety and technical capability of ultrasound
spectrum analysis to guide diﬀerential dose prostate LDR
brachytherapy. Thus far, 14 patients have been enrolled, and
we have found that the technique was feasible in all but
2 patients for a technical success rate of 86%. The tumor
regions are identiﬁed on the intraoperative ultrasound
spectrum analysis, and a brachytherapy treatment plan is
devised to treat the tumors to 200% of the prescription dose.
Standard plans were also created for each patient for com-
parison. Preliminary clinical and dosimetric results of the
trial in the ﬁrst 9 patients have also been encouraging [48].
The diﬀerential dose LDR brachytherapy plans successfully
escalated the dose to the tumors compared to what would
have been accomplished with a standard brachytherapy plan.
A mean of 98% of the tumor volume received at least
200% of the prescribed dose compared to only 55% with
the standard plans (P ≤ 0.0009). In addition, consistent
with the previously mentioned studies, there was statistically
signiﬁcant reduction in dose to the prostate gland outside
thetumorsseenwiththediﬀerentialdosebrachytherapy.The




Pure focal and diﬀerential therapy represents exciting
approaches to improve the therapeutic ratio of prostate
cancer treatment by decreasing complication risks while
maintaining or perhaps even improving cancer control rates.
Newer imaging modalities oﬀer accurate and noninvasive
methods for identifying intraprostatic tumors and can be
incorporated into treatment planning. Radiation therapy is
well suited for diﬀerential therapy, where treatment intensity
is increased towards the tumors and decreased in the
remaining prostate. Preliminary data using external beam
radiotherapy, HDR brachytherapy, and LDR brachytherapy
for diﬀerential therapy have been encouraging and shown
that these techniques are feasible and safe. Further areas of
study include deﬁning the optimal degree of dose escalation
tothetumorsanddosereductiontotheprostatethatprovide
the most favorable outcomes for patients and reﬁning the
technical procedures used to deliver this dose. In addition,
the possibility exists for using low-dose radiotherapy as an
adjunct to HIFU, cryotherapy, and other focal treatment
techniques. Additional clinical studies, and ultimately, large
randomized controlled trials are needed to validate these
approaches.
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